The final, formatted version of the article will be published soon.
CASE REPORT article
Front. Immunol.
Sec. Autoimmune and Autoinflammatory Disorders: Autoinflammatory Disorders
Volume 15 - 2024 |
doi: 10.3389/fimmu.2024.1418768
Incidentally cured psoriasis in a patient with refractory/relapsed diffuse large B-cell lymphoma receiving CD19 CAR-T cell therapy: a case report
Provisionally accepted- 1 Second Affiliated Hospital of Henan University of Science and Technology, Luoyang, China
- 2 Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, Henan Province, China
- 3 Blood Diseases Institute, Xuzhou Medical University, Xuzhou, Jiangsu Province, China
Chimeric antigen receptor T (CAR-T) cell therapy is a new treatment for cancers, but reports on curing immune-related skin diseases are limited. We report a case of successful CAR-T-cell therapy in a patient with refractory/relapsed diffuse large B-cell lymphoma (R/R DLBCL) who was incidentally cured of chronic generalized plaque psoriasis. The patient, a 65-year-old male who had a known history of psoriasis for 45 years, did not receive immunotherapy for psoriasis during this period. Imaging, molecular biology and immunology diagnostics confirmed DLBCL. After several weeks of standarddose R-CHOP chemotherapy, the patient achieved partial remission, but according to CT, the patient relapsed, and there was no significant improvement in her psoriasis symptoms. Subsequently, the patient was enrolled in the CD19 CAR-T-cell therapy group. Four weeks after CAR-T-cell infusion, the patient's abdominal pain disappeared, and there was a significant improvement in overall skin lesions. One year later, follow-up results indicated complete remission of R/R DLBCL (confirmed by PET-CT), with only minimal residual psoriatic skin lesions limited to the patient's neck. The results of using CAR-T-cell therapy to achieve an incidental cure for psoriasis highlight the potential for exploring cell-based therapies for complex autoinflammatory skin diseases.
Keywords: case report, CD19 CAR-T, Psoriasis, Refractory/Relapsed diffuse large B-cell lymphoma, Cell Therapy Trial registration: No. CT04666168
Received: 17 Apr 2024; Accepted: 02 Oct 2024.
Copyright: © 2024 Wang, An, Wang, Wang, Zhang, Xu, Guo, Gao, Li, Huang, Tian, Guo and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Wanhua An, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, Henan Province, China
Wanli Wang, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, Henan Province, China
Bin Zhang, Second Affiliated Hospital of Henan University of Science and Technology, Luoyang, China
Shuli Guo, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, Henan Province, China
Ming Gao, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, Henan Province, China
Bo Li, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, Henan Province, China
Lei Huang, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, Henan Province, China
Huanhuan Tian, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, Henan Province, China
Wenyi Guo, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, Henan Province, China
Huirui Wang, Second Affiliated Hospital of Henan University of Science and Technology, Luoyang, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.